Predicting whether a potential new anticancer agent will have a positive therapeutic index in patients remains a challenge. This brief review provides examples of preclinical in vivo/ex vivo and in situ assays used to assess the therapeutic potential of experimental anticancer therapeutics. Excision assays involving removal of tumor, bone marrow, and other tissues from the host after treatment to determine the effects of therapy in ex vivo assays are important preclinical tools. The survival of malignant cells from tumors treated in vivo and then excised is often determined by colony formation (CFU) in culture. When mice bearing in vivo alkylating agent-resistant tumors were treated with anticancer drugs such as cyclophosphamide, the survival pattern of bone marrow granulocyte-macrophage-colony forming units (CFU-GM) paralleled tumor cell survival. When TNP-470 and minocycline, an antiangiogenic combination, were added to treatment with cytotoxic anticancer therapies, tumor response markedly increased. TNP-470/minocycline-treated mice had higher tissue drug levels than did mice treated with the drug alone. Enzastaurin, an antiangiogenic protein kinase Cβ inhibitor, treatment decreased intratumoral vessels to one half to one quarter of controls. Simultaneous and sequential treatment regimens with enzastaurin and BCNU delayed tumor growth and increased lifespan in mice bearing subcutaneous or intracranial human T98G glioblastoma multiforme. Both TNP-470 and enzastaurin have undergone clinical trials. Enzastaurin is currently in Phase III clinical trials.
INTRODUCTION
Predicting from preclinical studies whether a potential new anticancer agent will have a positive therapeutic index in patients remains a challenge. Mice, the traditional preclinical host for cancer compound testing, tend to be more resilient to many xenobiotics and supranormal concentrations of protein molecules than are patients. Translational investigators probing deeper into the genomes of malignant diseases have described gene amplifications and deletions, rearrangements, and many silent and active mutations that are frequent in cancer (Chanock et al. 2007; Nicolau et al. 2007; Wang et al. 2006; Weir et al. 2007; Wood et al. 2007; Yosef et al. 2007 ). The plasticity and instability of the cancer genome is impressive. Most malignant tumors are unlikely to yield to single enzyme-targeted agents.
In the future therapeutic regimens may be selected based on the gene expression pattern or "molecular signature" or the level of specific proteins in an individual tumor. However, there will continue to be a need for broadly active anticancer agents in the long term. The current armamentarium of medical oncology includes many active anticancer agents that are applied across tumor types. None of the broadly active anticancer agents are ideal medications; however, for some diseases they are curative as sole therapy and for some diseases as adjuvant therapy. It is likely that combination regimens including cytotoxic anticancer agents and molecularly targeted agents will represent the next generation of successful cancer treatments. growth delay, and local tumor control, excision assays require removal of the tumor or normal tissue from the environment in which the treatment was delivered. This difference leads to several advantages and disadvantages to using excision assays. The ability to directly measure cell survival is an important advantage for both malignant and normal cells. The excision assay allows greater accuracy and discrimination among the effects of varied therapeutic regimens. Supralethal treatments can be tested, allowing more points of observation than can be achieved with in situ assays. Perhaps the greatest disadvantage of excision assays is that extended treatment regimens cannot be studied because cells that are killed by the treatments will lyse and thus be lost to measurement. Thus, an excision assay provides a snapshot of tumor and host response at a short time posttreatment (Rockwell 2002) . The survival of malignant cells from tumors treated in vivo and then excised is often determined by colony formation (CFU) in cell culture. Similarly, the survival of bone marrow cells from treated hosts is most often determined by colony formation and can be refined by use of growth factor supplements to the cell culture media to allow growth of specific progenitor cell types (Teicher 2002) .
APPLICATION OF IN VIVO/EX VIVO ASSAY TO PRIMARY AND METASTATIC DISEASE
The tumor excision and cell survival assay has been applied extensively to examine the response of primary tumors to therapy. This assay can also be applied to the detection of metastatic disease that is malignant cells residing in normal tissues, and to the response of metastatic disease to therapy (Holden et al. 1997) . For example, a study of the response of primary and metastatic tumor to antitumor alkylating treatment was carried out in mice bearing subcutaneously implanted EMT-6 mouse mammary carcinoma tumors. The tumor-bearing mice were treated with cyclophosphamide (300 or 500 mg/kg) as a single intraperitoneal injection on day 8 post-implantation of tumor cells. On day 8 after inoculation of the mice with the tumor cells, the subcutaneous tumor volumes were about 200 mm 3 . On day 9, the primary tumors, liver, lungs, blood, bone marrow, brain, and spleen were collected from the mice. The tissues were minced with crossed scalpels and then treated with DNase and collagenase to disaggregate the tissues into single cells (Table 1) . The enzyme exposure time was varied depending on the tissue to optimize the cell yield from each tissue. Known numbers of nucleated cells from each tissue were plated in monolayer culture under conditions suitable for EMT-6 tumor cell growth. After ten days of incubation, monolayer colonies of EMT-6 tumor cells were stained with crystal violet and counted (Holden et al. 1997) .
The data were expressed as tumor cell colonies per 10 6 nucleated cells plated from each tissue (Figure 1 ). In the absence of treatment, the subcutaneous primary tumor produced 2 x 10 4 colonies per 10 6 cells plated, and about 6000, 1000, and 500 tumor cell colonies grew from liver, lungs, and blood per 10 6 nucleated cell plated, respectively. Many fewer colonies, about 25, 2, and 1.5, grew from the bone marrow, brain, and spleen per 10 6 nucleated cells plated, respectively. These data reflect the relative abundance of viable malignant cells residing in these host normal tissues.
The response of the malignant cells to therapy varied markedly depending on the tissue in which the cells were located. Cyclophosphamide was used as a representative anticancer agent and was administered as a single dose to the tumorbearing mice. Tumor cells in the circulating blood and in the spleen were very sensitive to the cyclophosphamide treatment, and no tumor cell colonies grew from these tissues. Although the number of tumor cells in the brain was relatively few, most of them survived treatment of the host with cyclophosphamide and grew colonies. Tumor cells metastatic to the liver, bone marrow, and lungs were less responsive to treatment with cyclophosphamide than was the primary tumor, as evidenced by the shallower slope of the dose response curves for tumor in these organs compared with the slope of the response curve for the primary tumor ( Figure 1 ) (Holden et al. 1997) .
The reasons for the differential responsiveness of the EMT-6 tumor to cyclophosphamide depending on the location of the tumor cells in the host are manifold. There is heterogeneity in drug distribution throughout the host and variability in the capacity of the surrounding normal tissue of the host to detoxify the drug molecule. There are differences in the gene expression by tumor cells depending on the tissue microenvironment in which the tumor cells are residing.
IN VIVO-RESISTANT TUMORS
In vivo alkylating agent-resistant EMT-6 mouse mammary tumor lines were developed as a model of clinically relevant drug resistance, by treating tumor-bearing animals with cisplatin, carboplatin, cyclophosphamide, or thiotepa with transfer to fresh hosts ten times over six months (Teicher et al. 1990 ). In spite of the high levels of in vivo resistance, no difference in responsiveness was observed when cells from the parent and resistant tumors were exposed to the same drugs in monolayer cultures. The pharmacokinetics of cisplatin and cyclophosphamide were altered in mice bearing the respective resistant tumors compared with mice bearing the parental tumor and non-tumor-bearing mice. The resistance of the in vivo-resistant tumor lines decreased over three to six months when the tumor lines were passed in animals without further exposure to the drugs, indicating that the change in the response of the tumor cells to the drugs was likely epigenetic.
The survival of bone marrow CFU-GM was assessed in mice bearing the EMT-6/parent tumor or in vivo-resistant tumors (Chatterjee et al. 1995; Teicher et al. 1990; Teicher, Chatterjee et al. 1993) . Surprisingly, the survival pattern of the bone marrow recapitulated the survival of the tumor cells, mimicking the development of resistance and reversion to sensitivity on removal of the selection pressure for each of the four alkylating agents. When EMT-6/parent tumor cells were implanted in the opposite hind limb of animals bearing the in vivo-resistant tumors, the response of the parental tumor cells after treatment of the animals with the appropriate antitumor alkylating agent was decreased, indicating that the presence of an alkylating agent-resistant tumor in a host altered the drug response of normal tissues and tumor throughout the host ( Figure 2) (Chatterjee et al. 1995; Teicher et al. 1990; Teicher, Chatterjee et al. 1993) .
Understanding the mechanisms involved in the sensitivity/ resistance of tumors to chemotherapy coupled with the development of a clinically relevant means of ensuring tumor sensitivity is an important continuing endeavor (Brandes et al. 2002; Perry et al. 2002; Veroski et al. 2002) . To explore the mechanisms of drug resistance, transcriptional profiling was performed on Affymetrix arrays using RNA from the parental and in vivoresistant tumors (Perry et al. 2002) . RNA was extracted from three tumors for each line and independently hybridized to the microarrays. Hybridization intensities were normalized to permit direct comparisons between samples. One to two percent of the genes from the in vivo resistant tumors showed at least twofold changes in mean hybridization intensities compared with the parental tumor. A small subset of genes had significant expression changes across the resistant tumor lines (Brandes et al. 2002; Perry et al. 2002) . Transforming growth factor-β (TGF-β), platelet-derived growth factor (PDGFR), and mitogenactivated protein kinase (MAPK) genes were increased in expression in the resistant tumors. These changes were confirmed by Western blot. Thus, factors associated with increased angiogenesis and immunosupression were upregulated in the resistant tumor lines.
COMBINATION REGIMENS

TNP-470/Minocycline
The combination of TNP-470 and minocycline is an example of an antiangiogenic treatment regimen. In mice, treatment with the antiangiogenic combination of TNP-470 and minocycline for two weeks did not alter the growth of the Lewis lung carcinoma, the EMT mouse mammary carcinoma, the FSaIIC mouse fibrosarcoma, or the rat 9L gliosarcoma (Teicher et al. 1992; Teicher et al. 1994; Teicher, Dupuis, Robinson et al. 1995; Teicher, Dupuis, Kusumoto et al. 1995; Teicher, Holden, Ara et al. 1995; . However, when TNP-470 and minocycline were added to treatment with cytotoxic anticancer therapies, tumor response was markedly increased. When C3H mice bearing the FSaIIC fibrosarcoma were treated with TNP-470/minocycline for five days prior to intravenous injection of the fluorescent FIGURE 2.-Survival, determined by colony formation, of EMT-6 mouse mammary tumor cells and EMT-6/CTX mouse mammary tumor cells resistant to cyclophosphamide in vivo after treatment of the tumor-bearing mice with a single dose of cyclophosphamide (100, 300, or 500 mg/kg) by intraperitoneal injection. The animals were treated on day 8 post-tumor implantation, and tissues were collected on day 9. Surviving fraction is calculated by comparison with untreated controls. dye Hoechst 33342, followed by excision of the tumor, preparation of a single-cell suspension of tumor cell and of the tumor cell population by fluorescence-activated cell sorting, there was a shift of the entire tumor cell population toward greater brightness. The 10% brightest cell and the 20% dimmest cell subpopulations were composed of cells containing much more fluorescent dye than the same subpopulations of cells from the control tumor ( Figure 3 ) (Teicher et al. 1994) . The TNP-470/ minocycline-treated tumors were more easily penetrated by the lipophilic dye. This was the first indication that TNP-470 and minocycline treatment might allow greater distribution of small molecules into tumors and provided evidence that treatment with antiangiogenic agents was able to increase the response of tumor to therapy.
To explore this observation further, Lewis lung carcinomabearing mice were treated for five days with TNP-470/minocyline and then injected intraperitoneally with [ 14 C]-cyclophosphamide, and six hours later tissues were collected. There were higher [ 14 C]-levels in the tissues of the mice treated with TNP-470/ minocycline than in the tissues of the mice treated with cyclophosphamide alone. The tissues that showed changes were primary subcutaneous tumor, liver, kidney, brain, heart, gut, skin, muscle, and lung. The largest increases were 2.6-fold in the tumor, 2.3-fold in the kidney, 3.2-fold in the heart, 5.6-fold in the gut, and 7.9-fold in skeletal muscle (Teicher, Dupuis, Robinson et al. 1995) . A similar study was carried out with TNP-470/minocycline with cisplatin or cisplatin treatment alone. The platinum levels in the tissues were determined by atomic absorption spectroscopy. There were increased levels of platinum in all of the tissues taken from animals treated with TNP-470/minocycline compared with animals treated with cisplatin only. The largest increases were 5.2-fold in the tumor, 3.8-fold in the gut, 3.0-fold in the skin and 2.5-fold in the skeletal muscle (Teicher, Dupuis, Robinson et al. 1995) .
[ 14 C]Paclitaxel was administered to Lewis lung carcinomabearing mice either treated for five days with TNP-470/ minocyline or not, and tissues were collected over a twenty-fourhour time course (Herbst et al. 1998) . The pattern of [ 14 C]paclitaxel distribution into tumor and other tissues was similar, with higher peak levels of [ 14 C]paclitaxel in the tissues of mice pretreated with TNP-470/minocycline. The highest levels of [ 14 C]paclitaxel were in the lungs of mice that had received TNP-470/minocycline. Other tissues with high paclitaxel concentrations were gut and heart. To determine whether treatment with TNP-470/minocycline would alter the tissue distribution of large molecules into tumors and normal tissues, [ 14 C]albumin was administered to TNP-470/minocycline-treated mice bearing the Lewis lung carcinoma and untreated animals (Herbst et al. 1998 ). There was a two-to three-fold higher concentration of [ 14 C]albumin in the tumors and normal tissues of mice treated with TNP-470/ minocycline than in untreated mice during the initial hours after [ 14 C]albumin injection. A differential in [ 14 C]albumin tumor and normal tissues levels persisted over the twenty-four-hour period post [ 14 C]albumin injection examined with TNP-470/ minocycline-treated mice that had higher levels. The highest levels of [ 14 C]albumin were in liver and lungs.
The Lewis lung tumor growing subcutaneously in C57Bl mice is very hypoxic, with 92% of the pO 2 measurements ≤ 5mmHg (radiobiologic hypoxia), as determined with a polarographic oxygen electrode (Teicher, Dupuis, Kusumoto et al. 1995) . In Lewis lung tumor-bearing mice treated with TNP-470/minocyline for five days, the percentage of pO 2 readings ≤ 5mmHg was 75%. When the mice were administered an oxygen delivery agent and allowed to breathe a 95% oxygen atmosphere, the percentage of pO 2 readings ≤ 5mmHg was decreased to 45%, and the response of the tumors to fractionated radiation therapy markedly increased. There was a linear relationship between the decreases in the percentage of pO 2 readings ≤ 5mmHg and tumor response at each radiation dose (2, 3, and 4 Gray x 5), indicating that the diminution in tumor hypoxia produced by the treatment may be directly responsible for the increase in the effectiveness of the radiation therapy.
The effect of treatment with TNP-470/minocycline on the number of countable intratumoral blood vessels was examined in mice bearing the Lewis hung carcinoma ( Table 2) . Treatment of the tumor-bearing animals with TNP-470 (30 mg/kg) on alternate days by subcutaneous injection for five doses decreased the number of intratumoral vessels to 51% of the number found in the untreated controls. Interestingly, treatment with TNP-470 and minocycline (10 mg/kg) daily by intraperitoneal injection was somewhat less effective in decreasing the number of intratumoral vessels and resulted in tumors, with about 64% of the number of vessels counted in the control tumors. Both cyclophosphamide and cisplatin are cytotoxic through the formation of cross-links in cellular DNA. DNA alkaline elution was performed with DNA isolated from tumors treated in vivo, and there was increased DNA cross-linking with increasing dose of cyclophosphamide (Table 3) (Teicher, Dupuis, Robinson et al. 1995) . Treatment of Lewis lung carcinomabearing mice with cyclophosphamide (300 mg/kg) resulted in a cross-linking factor of 4.7. Treatment of the mice with TNP-470/minocycline along with cyclophosphamide resulted in a DNA cross-linking factor of 6.2, which extrapolates to an equivalency of about 650 mg/kg of cyclophosphamide. Increased DNA cross-linking was also detected with administration of cisplatin to mice bearing the Lewis lung carcinoma. Treatment with cisplatin (20 mg/kg) alone resulted in a crosslinking factor of 2.0. Treatment of tumor-bearing mice with TNP-470/minocycline and cisplatin resulted in a DNA crosslinking factor of 8.9, which extrapolates to an equivalency of about 85 mg/kg of cisplatin.
Enzastaurin
Enzastaurin is a potent inhibitor of PKCβ and an antiangiogenic agent . PKCβ promoter activity and PKCβ mRNA expression in HCT116 cells were inhibited enzastaurin demonstrating autoregulation of PKCβ expression. Endogenous PKCβ mRNA levels in HCT116 cells were significantly reduced by enzastaurin, consistent with the effect on PKCβ promoter activity (Liu et al. 2004 ). Exposure to a range of concentrations of enzastaurin inhibited proliferation of vascular endothelial growth factor (VEGF) (20 ng/mL)-stimulated human umbilical vein endothelial cells (HUVEC). When human SW2 small cell lung carcinoma cells were exposed to a range of concentrations of enzastaurin, a potency differential on the malignant cells versus HUVEC was apparent ( Figure 4 ). Exposure to enzastaurin can cause growth inhibition and apoptosis of human multiple myeloma cells, diffuse large cell lymphoma cells, and mantle cell lymphoma cells (Rieken et al. 2005; Rizvi et al. 2005; Rossi et al. 2005; Podar et al. 2007) .
Additional evidence of antiangiogenic activity was obtained when enzastaurin was administered orally to Fisher 344 female rats bearing ocular implants of VEGF-impregnated filters. Ten days of treatment resulted in markedly decreased vascular growth in the corneas. A dose of 30 mg/kg of enzastaurin decreased vascular growth to the level of the unstimulated surgical control ( Figure 5) . Administration of enzastaurin (30 mg/kg) orally twice per day on days 1 through 10 post-surgical implantation of bFGF resulted in decreased vascular growth to a level of 26% of the bFGF control ( Figure 5) .
Nude mice bearing subcutaneous human tumor xenografts were treated with enzastaurin orally twice daily on days 4 through 14 or 14 through 30 post-tumor cell implantation. Tumors were collected and immunohistochemically stained for expression of endothelial cell-specific markers (CD105 or CD31). The number of intratumoral blood vessels in the samples was quantified by counting stained regions in ten high-power microscope fields (200x). The number of intratumoral vessels was decreased to one half to one quarter of the controls in animals treated with enzastaurin (30 mg/kg) (Table 4) (Keyes et al. 2002; Keys et al. 2003; Teicher et al. 2002; Teicher, Menon, Alvarez, Galbreath et al. 2001; Teicher, Menon, Alvarez, Liu et al. 2001) . Although some of the tumors responded to enzastaurin as an antiangiogenic agent, in no case was angiogenesis completely blocked, as in the rat corneal micropocket neoangiogenesis model. Tumor response to enzastaurin treatment did not correlate with intratumoral vessel decrease (Table 4) .
To explore the effect of enzastaurin on a circulating angiogenic factor in tumor-bearing mice, plasma VEGF was measured in mice bearing the human SW2 small cell lung carcinoma, Caki-1 renal cell carcinoma, or HCT116 colon carcinoma (Keys et al. 2004; Lee et al. 2008; Spalding et al. 2007 ). Plasma samples were obtained every three days starting on day 7 postimplantation and continued through treatment and after treatment. Plasma VEGF was undetectable until tumor volumes were 500-600 mm 3 and was similar in the treated and untreated groups through day 20, when plasma VEGF reached 75 pg/mL ( Figure 6 ). Plasma VEGF in the SW2 control group continued to increase and reached 400 pg/mL on day 40 after tumor implantation. Upon termination of treatment, plasma VEGF slightly increased to 100 ng/mL, which was still significantly decreased compared to the untreated control group. Plasma VEGF in the control Caki-1 group continued to increase and peaked at 225 pg/mL on day 49 post tumor implantation. In the treatment group, the plasma VEGF remained suppressed compared to controls through the treatment (days 21-39). The plasma VEGF, reaching a maximum of 37 pg/mL, remained suppressed to day 53, which was fourteen days after terminating treatment (Keys et al. 2004; Lee et al. 2008; Spalding et al. 2007 ). Tumor volumes were followed in the same cohorts of mice. Tumor growth did not slow when plasma VEGF decreased; however, some decrease in tumor growth was evident in the treated groups late in the experiment (Figure 7) . In most tumor models, the tumor growth delay produced by enzastaurin as a single agent was not sufficient to predict single agent activity in the clinic. However, the combination regimens suggested high activity.
Simultaneous and sequential treatment regimens combining treatment with enzastaurin and BCNU were studied in human T98G glioblastoma multiforme using tumor growth delay as the response end point when the tumor was implanted subcutaneously and increase-in-lifespan as the end point when the tumor was implanted intracranially (Keys et al. 2003) . For the simultaneous treatment regimen, enzastaurin was administered on days 4-18, and BCNU was administered on days 7-11 after tumor implantation. In this tumor model, treatment with enzastaurin produced tumor growth delays of 6.0 and 8.6 days at doses of 10 and 30 mg/kg, respectively ( Figure 8B ). Administration of the combination of enzastaurin (30 mg/kg) with BCNU resulted in a tumor growth delay of 15.2 days. Nude mice implanted with T98G (10 4 cells) intracranially had a mean survival time of thirty-seven days. Administration of enzastaurin (30 mg/kg) alone doubled the survival time, producing a mean survival time of seventy-two days ( Figure 8A ). Administration of BCNU to mice bearing the intracranial tumor implant et al. 2003) . Enzastaurin efficacy in the sequential treatment regimen after completion of BCNU was examined over a dosage range from 3 to 30 mg/kg. Enzastaurin alone on days 12-30 produced tumor growth delays of 18.5-32.6 days, respectively, in the subcutaneous T98G tumor ( Figure 8D ). BCNU treatment followed by enzastaruin (30 mg/kg) resulted in a tumor growth delay of 46.8 days. Delaying treatment with enzastaurin (3 to 30 mg/kg) from day 4 to day 12 after intracranial T98G tumor implant produced mean survival times from fifty-seven to seventy-two days compared with thirty-seven days for controls ( Figure 8C ). BCNU treatment followed by enzastaurin (3 to 30 mg/kg) resulted in mean survival times from sixty-three to seventy-four days compared with forty-one days for BCNU alone (Keys et al. 2003) .
CONCLUSION
Tumor in vivo/ex vivo assays and in situ assays are used to assess the antitumor activity and therapeutic potential of experimental oncology therapeutics. These assays can also further our understanding of malignant disease biology and metastatic spread. From the examples discussed in this brief review, TNP-470 and other molecules of the fumagillin class have been found to inhibit the enzyme methionine aminopeptidase-2 (MetAP-2) (Bernier et al. 2005) . TNP-470 has undergone phase I and phase II clinical testing Bhargava et al. 2000; Blumenschein et al. 2002; Herbst et al. 2000; Tran et al. 2001) . Although TNP-470 demonstrated encouraging activity alone and in combination with cytotoxic anticancer agents, dose-limiting reversible CNS toxicities including effects on neurocognitive function and on motor coordination and a poor clinical pharmacokinetic profile resulted in the discontinuation of TNP-470 clinical development. TNP-470 continues to be explored preclinically in a variety of tumor models, including orthotopic anaplastic thyroid cancer, orthotopic prostate cancer, and endometriosis (Becker et al. 2007; Kosharskyy et al. 2006; Nahari et al. 2007) . A promising new direction has been conjugation of TNP-470 to a HPMA copolymer (Chesler et al. 2007; Rihova et al. 2007; Satchi-Fainaro et al. 2004; Satchi-Fainaro et al. 2005) . A water-soluble copolymer based on N-(2-hydroxypropyl)methacrylamide (HPMA)-TNP-470 conjugate (caplostatin) may overcome the limitations of the TNP-470 small molecule. Caplostatin appears to have similar efficacy to TNP-470 without weight loss or neurotoxicity in mouse tumor models. In addition, new analogs of TNP-470 such as PPI-2458 and fumarranol, a rearranged fumigillin analog, retain the antiangiogenic activity of TNP-470 and may have reduced toxicity (Bernier et al. 2005; Lu et al. 2006) .
Enzastaurin completed single-agent phase I clinical studies in healthy subjects and in cancer patients (Carducci et al. 2006; Herbst et al. 2002; Welch et al. 2007 ). Single-agent phase II studies were conducted in patients with relapsed diffuse large B-cell lymphoma and in patients with recurrent high-grade gliomas. Several patients with multiple relapsed diffuse large B-cell lymphomas achieved prolonged periods of stable disease following enzastaurin treatment, although the objective tumor FIGURE 7.-Tumor volumes in nude mice bearing human SW2 SCLC, Caki-1 renal cell carcinoma or HCT116 colon carcinoma xenograft tumors, either untreated controls or treated with enzastaurin orally twice daily, days 14-30 (21-39 for Caki-1-bearing mice). The data represent the average results for three trials, with each point being the average of nine individual tumors. Bars represent SEM. Asterisk indicates statically significant differences (P < .05). FIGURE 8.-A. Survival of animals bearing intracranial human T98G glioblastoma multiforme after treatment with enzastaurin (3, 10, or 30 mg/kg, po) twice per day on days 12-30 alone or with BCNU (15 mg/kg, ip) on days 7-11. B. Survival of animals bearing intracranial human T98G glioblastoma multiforme after treatment with enzastaurin (10 or 30 mg/kg, po) twice per day on days 4-18 alone or with BCNU (15 mg/kg, ip) on days 7-11. C. Growth delay of subcutaneous T98G glioblastoma multiforme after treatment with enzastaurin (10 or 30 mg/kg, po) twice per day on days 4-18 alone or with BCNU (15 mg/kg, ip) on days 7-11. D. Growth delay of subcutaneous T98G glioblastoma multiforme after treatment with enzastaurin (3, 10, or 30 mg/kg, po) twice per day on days 12-30 alone or with BCNU (15 mg/ kg, ip) on days 7-11. Data are the means of five animals ± SEM. response rate was low (Robertson et al. 2007) . In a single-agent phase II study in patients with relapsed or refractory mantle cell lymphoma, freedom from progression was achieved in six out of 660 patients, with minimal toxicity (Ma and Rosen 2007; Morschhauser et al. 2008) . Phase I clinical trials of enzastaurin in combination with capecitabine in patients with advanced solid tumors and in combination with gemcitabine and cisplatin in patients with advanced cancer identified doses of enzastaurin that could be recommended for phase II studies of these regimens (Camidge et al. 2008; Rademaker-Lakhai et al. 2007) . Enzastaurin, as a single agent in varied combination regimens, is currently under investigation in metastatic non-small cell lung cancer, metastatic breast cancer, gliobastoma multiforme, and bladder cancer (Herbst et al. 2007; Oh et al. 2008 ).
